Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-20T00:16:41.420Z Has data issue: false hasContentIssue false

Chapter 10 - Pancreas and liver

from Part II - Oncologic applications

Published online by Cambridge University Press:  05 September 2012

Victor H. Gerbaudo
Affiliation:
Brigham and Women's Hospital, Harvard Medical School
Get access

Summary

Pancreatic cancer

General concepts and epidemiology

According to the American Cancer Society, it is estimated that 43,140 Americans will be diagnosed with pancreatic carcinoma in 2010 with an estimated 36,800 deaths. This represents the 10th most commonly diagnosed malignancy, but the fourth leading cause of cancer-related death (1). Pancreatic adenocarcinoma is one of the most lethal of all malignancies with a 1-year survival of 20–25% and a 5-year survival rate of approximately 5% (2). Survival for pancreatic adenocarcinoma remains dismally low despite advances in diagnostic and therapeutic development over the past several years. Currently, the only potentially curative treatment is surgical resection, which is only an option for 15–20% of patients. For those who are surgical candidates, 5-year survival following pancreaticoduodenectomy remains low at 25–30% in patients with no nodal involvement.

Tumors arising from the pancreas can be exocrine or endocrine in origin. The most common type of exocrine tumor of the pancreas is ductal adenocarcinoma. Adenosquamous, squamous, and giant cell tumors are much less common. Acinar cell carcinomas are rare and have a similar prognosis as for ductal carcinoma. Pancreatic neuroendocrine tumors such as insulinoma, glucagonoma, and gastrinoma are uncommon and are often associated with other endocrine abnormalities. Pancreatic endocrine tumors are usually slow growing and are typically found in the body or tail of the pancreas. Benign cysts, pseudocysts, and cystadenomas may occur within the pancreas, although malignant cystic neoplasms may also occur.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Jemal, ASiegel, RXu, JWard, E.Cancer statistics, 2010CA Cancer J Clin 2010 60 277CrossRefGoogle ScholarPubMed
Horner, MJRies, LAGKrapcho, MSEER Cancer Statistics Review, 1975–2006Bethesda, MDNational Cancer Institutehttp://seer.cancer.gov/csr/1975_2006/ 2008Google Scholar
Katz, MHHwang, RFleming, JBEvans, DB.Tumor-node-metastasis staging of pancreatic adenocarcinomaCA Cancer J Clin 2008 58 111CrossRefGoogle ScholarPubMed
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
Ichikawa, TErturk, SMSou, HMDCT of pancreatic adenocarcinoma: optimal imaging phases and multiplanar reformatted imagingAm J Roentgenol 2006 187 1513CrossRefGoogle ScholarPubMed
Vargas, RNino-Murcia, MTrueblood, WJeffrey, RBMDCT in pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformationsAm J Roentgenol 2004 182 419CrossRefGoogle ScholarPubMed
DeWitt, JDevereaux, BChriswell, MComparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancerAnn Intern Med 2004 141 753CrossRefGoogle ScholarPubMed
Lammer, JHerlinger, HZalaudek, GHofler, H.Pseudotumorous pancreatitisGastrointest Radiol 1985 10 59CrossRefGoogle ScholarPubMed
NIH state-of-the-sciencestatement on endoscopic retrograde cholangiopancreatography (ERCP) for diagnosis and therapyNIH Consens State Sci Statements 2002 19 1Google Scholar
Erickson, RA.ERCP and pancreatic cancerAnn Surg Oncol 2004 11 555CrossRefGoogle ScholarPubMed
Ichikawa, THaradome, HHachiya, JPancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imagingRadiology 1997 202 655CrossRefGoogle ScholarPubMed
Lopez Hanninen, EAmthauer, HHosten, NProspective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiographyRadiology 2002 224 34CrossRefGoogle ScholarPubMed
Yeo, CJCameron, JLLillemoe, KDPancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortalityAnn Surg 2002 236 355CrossRefGoogle ScholarPubMed
Delbeke, DMartin, WH.PET and PET/CT for pancreatic malignanciesSurg Oncol Clin N Am 2010 19 235CrossRefGoogle ScholarPubMed
Monakhov, NKNeistadt, ELShavlovskil, MMShvartsman, ALNeifakh, SA.Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissuesJ Natl Cancer Inst 1978 61 27CrossRefGoogle ScholarPubMed
Higashi, TTamaki, NHonda, TExpression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET studyJ Nucl Med 1997 38 1337Google ScholarPubMed
Reske, SNGrillenberger, KGGlatting, GOverexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinomaJ Nucl Med 1997 38 1344Google ScholarPubMed
Delbeke, DPinson, CW.Pancreatic tumors: role of imaging in the diagnosis, staging, and treatmentJ Hepatobiliary Pancreat Surg 2004 11 4CrossRefGoogle Scholar
Kauhanen, SPKomar, GSeppanen, MPA prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancerAnn Surg 2009 250 957CrossRefGoogle Scholar
Gambhir, SSCzernin, JSchwimmer, JA tabulated summary of the FDG PET literatureJ Nucl Med 2001 42 1SGoogle ScholarPubMed
Rose, DMDelbeke, DBeauchamp, RD18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancerAnn Surg 1999 229 729CrossRefGoogle ScholarPubMed
Nakata, BNishimura, SIshikawa, TPrognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancerInt J Oncol 2001 19 53Google ScholarPubMed
Zimny, MFass, JBares, RFluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinomaScand J Gastroenterol 2000 35 883Google ScholarPubMed
Sperti, CPasquali, CDecet, GF-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective studyJ Gastrointest Surg 2005 9 22CrossRefGoogle ScholarPubMed
Delbeke, DRose, DMChapman, WCOptimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinomaJ Nucl Med 1999 40 1784Google ScholarPubMed
Heinrich, SGoerres, GWSchafer, MPositron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectivenessAnn Surg 2005 242 235CrossRefGoogle ScholarPubMed
Ruf, JLopez Hanninen, EOettle, HDetection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRIPancreatology 2005 5 266CrossRefGoogle ScholarPubMed
Kitajima, KMurakami, KYamasaki, EPerformance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CTMol Imaging Biol 2010CrossRefGoogle Scholar
Bang, SChung, HWPark, SWThe clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancerJ Clin Gastroenterol 2006 40 923CrossRefGoogle ScholarPubMed
Kuwatani, MKawakami, HEto, KModalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markersIntern Med 2009 48 867CrossRefGoogle ScholarPubMed
Bosch, FXRibes, JDiaz, MCleries, R.Primary liver cancer: worldwide incidence and trendsGastroenterology 2004 127 S5CrossRefGoogle ScholarPubMed
El-Serag, HBDavila, JAPetersen, NJMcGlynn, KA.The continuing increase in the incidence of hepatocellular carcinoma in the United States: an updateAnn Intern Med 2003 139 817CrossRefGoogle ScholarPubMed
Russo, MWWei, JTThiny, MTDigestive and liver diseases statistics, 2004Gastroenterology 2004 126 1448CrossRefGoogle ScholarPubMed
McCaughan, GWKoorey, DJStrasser, SI.Hepatocellular carcinoma: current approaches to diagnosis and managementIntern Med J 2002 32 394CrossRefGoogle ScholarPubMed
Fattovich, GGiustina, GDegos, FMorbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patientsGastroenterology 1997 112 463CrossRefGoogle ScholarPubMed
Levy, IGreig, PDGallinger, SLanger, BSherman, M.Resection of hepatocellular carcinoma without preoperative tumor biopsyAnn Surg 2001 234 206CrossRefGoogle ScholarPubMed
Torzilli, GMinagawa, MTakayama, TAccurate preoperative evaluation of liver mass lesions without fine-needle biopsyHepatology 1999 30 889CrossRefGoogle ScholarPubMed
Koteish, AThuluvath, PJ.Screening for hepatocellular carcinomaJ Vasc Interv Radiol 2002 13 S185CrossRefGoogle ScholarPubMed
Fung, KTLi, FTRaimondo, MLSystematic review of radiological imaging for hepatocellular carcinoma in cirrhotic patientsBr J Radiol 2004 77 633CrossRefGoogle ScholarPubMed
Weber, GCantero, A.Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissuesCancer Res 1955 15 105Google ScholarPubMed
Weber, GMorris, HPComparative biochemistry of hepatomas. III. Carbohydrate enzymes in liver tumors of different growth ratesCancer Res 1963 23 987Google ScholarPubMed
Torizuka, TTamaki, NInokuma, TIn vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PETJ Nucl Med 1995 36 1811Google ScholarPubMed
Trojan, JSchroeder, ORaedle, JFluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinomaAm J Gastroenterol 1999 94 3314CrossRefGoogle ScholarPubMed
Iwata, YShiomi, SSasaki, NClinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumorsAnn Nucl Med 2000 14 121CrossRefGoogle Scholar
Delbeke, DMartin, WHSandler, MPEvaluation of benign vs malignant hepatic lesions with positron emission tomographyArch Surg 1998 133 510CrossRefGoogle ScholarPubMed
Khan, MACombs, CSBrunt, EMPositron emission tomography scanning in the evaluation of hepatocellular carcinomaJ Hepatol 2000 32 792CrossRefGoogle ScholarPubMed
Liangpunsakul, SAgarwal, DHorlander, JCKieff, BChalasani, N.Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotics awaiting for liver transplantationTransplant Proc 2003 35 2995CrossRefGoogle ScholarPubMed
Wudel, LJDelbeke, DMorris, DThe role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinomaAm Surg 2003 69 117Google Scholar
Chen, YKHsieh, DSLiao, CSUtility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrenceAnticancer Res 2005 25 4719Google ScholarPubMed
Delbeke, DPinson, CW11C-acetate: a new tracer for the evaluation of hepatocellular carcinomaJ Nucl Med 2003 44 222Google ScholarPubMed
Ho, CLYu, SCYeung, DW11C-acetate PET imaging in hepatocellular carcinoma and other liver massesJ Nucl Med 2003 44 213Google ScholarPubMed
Ho, CLChen, SYeung, DWCheng, TK.Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinomaJ Nucl Med 2007 48 902CrossRefGoogle ScholarPubMed
Park, JWKim, JHKim, SKA prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinomaJ Nucl Med 2008 49 1912CrossRefGoogle ScholarPubMed
Aljiffry, MAbdulelah, AWalsh, MEvidence-based approach to cholangiocarcinoma: a systematic review of the current literatureJ Am Coll Surg 2009 208 134CrossRefGoogle ScholarPubMed
de Groen, PCGores, GJLaRusso, NFGunderson, LLNagorney, DM.Biliary tract cancersN Engl J Med 1999 341 1368CrossRefGoogle ScholarPubMed
Nakeeb, APitt, HASohn, TACholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumorsAnn Surg 1996 224 463CrossRefGoogle ScholarPubMed
Chung, YEKim, MJPark, YNVarying appearances of cholangiocarcinoma: radiologic-pathologic correlationRadiographics 2009 29 683CrossRefGoogle ScholarPubMed
Anderson, CDRice, MHPinson, CWFluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinomaJ Gastrointest Surg 2004 8 90CrossRefGoogle ScholarPubMed
Moon, CMBang, SChung, JBUsefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomasJ Gastroenterol Hepatol 2008 23 759CrossRefGoogle ScholarPubMed
Kim, YJYun, MLee, WJKim, KSLee, JD.Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinomaEur J Nucl Med Mol Imaging 2003 30 1467CrossRefGoogle ScholarPubMed
Corvera, CUBlumgart, LHAkhurst, T18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancerJ Am Coll Surg 2008 206 57CrossRefGoogle ScholarPubMed
Donohue, JHStewart, AKMenck, HR.The National Cancer Data Base report on carcinoma of the gallbladder, 1989–1995Cancer 1998 83 26183.0.CO;2-H>CrossRefGoogle ScholarPubMed
Goldin, RDRoa, JC.Gallbladder cancer: a morphological and molecular updateHistopathology 2009 55 218CrossRefGoogle ScholarPubMed
Lazcano-Ponce, ECMiquel, JFMunoz, NEpidemiology and molecular pathology of gallbladder cancerCA Cancer J Clin 2001 51 349CrossRefGoogle ScholarPubMed
Duffy, ACapanu, MAbou-Alfa, GKGallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)J Surg Oncol 2008 98 485CrossRefGoogle Scholar
Hoh, CKHawkins, RAGlaspy, JACancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucoseJ Comput Assist Tomogr 1993 17 582CrossRefGoogle ScholarPubMed
Lomis, KDVitola, JVDelbeke, DRecurrent gallbladder carcinoma at laparoscopy port sites diagnosed by positron emission tomography: implications for primary and radical second operationsAm Surg 1997 63 341Google ScholarPubMed
Rodriguez-Fernandez, AGomez-Rio, MLlamas-Elvira, JMPositron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosisAm J Surg 2004 188 171CrossRefGoogle ScholarPubMed
Lee, SWKim, HJPark, JHClinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinomaJ Gastroenterol 2010Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×